These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24206020)

  • 1. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure.
    Chang J; Leong RW
    Expert Opin Biol Ther; 2014 Jan; 14(1):27-36. PubMed ID: 24206020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe handling of monoclonal antibodies: Too large to be hazardous?
    de Lemos ML; Badry N; Kletas V; Fabbro J; Tew A
    J Oncol Pharm Pract; 2018 Apr; 24(3):218-220. PubMed ID: 29284346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel.
    Alexander M; King J; Bajel A; Doecke C; Fox P; Lingaratnam S; Mellor JD; Nicholson L; Roos I; Saunders T; Wilkes J; Zielinski R; Byrne J; MacMillan K; Mollo A; Kirsa S; Green M
    Intern Med J; 2014 Oct; 44(10):1018-26. PubMed ID: 25302720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
    Le Bidre E; Chaby G; Martin L; Perrussel M; Sassolas B; Sigal ML; Kaassis C; Lespessailles E; Nseir A; Estève E
    Ann Dermatol Venereol; 2011; 138(4):285-93. PubMed ID: 21497255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safe handling of cytotoxic and hazardous drugs].
    Imamura S; Hardy A
    Kango; 1991 Apr; 43(5):149-56. PubMed ID: 1841137
    [No Abstract]   [Full Text] [Related]  

  • 10. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guidelines for the health protection and safety of workers exposed to antineoplastic drugs].
    Palazzo S; Bernardo G; Draicchio F; Lucchini R; Merlano M; Minguzzi M; Molinaro V; Scanni A; Sossai D; Villa L
    Med Lav; 1996; 87(3):255-64. PubMed ID: 8965737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
    Eshuis EJ; Griffioen GH; Stokkers PC; Ubbink DT; Bemelman WA
    Colorectal Dis; 2012 May; 14(5):578-84. PubMed ID: 21848898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
    Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
    J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
    Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
    Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding accidental exposure to intravenous cytotoxic drugs.
    Meade E
    Br J Nurs; 2014 Sep 11-24; 23(16):S34, S36-9. PubMed ID: 25203853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe handling of hazardous drugs.
    Polovich M
    Online J Issues Nurs; 2004 Sep; 9(3):6. PubMed ID: 15482092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.